Rucaparib is a PARP inhibitor widely used in treating advanced ovarian, fallopian tube, and prostate cancers. It works by targeting cancer cells with BRCA mutations, preventing their repair and growth. Patients benefit from its targeted mechanism, leading to improved outcomes with manageable...